ABT Butterfly Strategy
ABT (Abbott Laboratories), in the Healthcare sector, (Medical - Devices industry), listed on NYSE.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders.
ABT (Abbott Laboratories) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $146.00B, a trailing P/E of 23.33, a beta of 0.65 versus the broader market, a 52-week range of 81.97-139.06, average daily share volume of 13.0M, a public-listing history dating back to 1980, approximately 114K full-time employees. These structural characteristics shape how ABT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.65 indicates ABT has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. ABT pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.
What is a butterfly on ABT?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current ABT snapshot
As of May 15, 2026, spot at $84.50, ATM IV 28.79%, IV rank 65.68%, expected move 8.25%. The butterfly on ABT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 28-day expiry.
Why this butterfly structure on ABT specifically: ABT IV at 28.79% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 8.25% (roughly $6.97 on the underlying). The 28-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ABT expiries trade a higher absolute premium for lower per-day decay. Position sizing on ABT should anchor to the underlying notional of $84.50 per share and to the trader's directional view on ABT stock.
ABT butterfly setup
The ABT butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ABT near $84.50, the first option leg uses a $80.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ABT chain at a 28-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ABT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $80.00 | $5.50 |
| Sell 2 | Call | $84.00 | $3.10 |
| Buy 1 | Call | $89.00 | $0.95 |
ABT butterfly risk and reward
- Net Premium / Debit
- -$25.00
- Max Profit (per contract)
- $366.96
- Max Loss (per contract)
- -$125.00
- Breakeven(s)
- $80.14, $87.75
- Risk / Reward Ratio
- 2.936
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
ABT butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on ABT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$25.00 |
| $18.69 | -77.9% | -$25.00 |
| $37.37 | -55.8% | -$25.00 |
| $56.06 | -33.7% | -$25.00 |
| $74.74 | -11.6% | -$25.00 |
| $93.42 | +10.6% | -$125.00 |
| $112.10 | +32.7% | -$125.00 |
| $130.79 | +54.8% | -$125.00 |
| $149.47 | +76.9% | -$125.00 |
| $168.15 | +99.0% | -$125.00 |
When traders use butterfly on ABT
Butterflies on ABT are pinning bets - traders use them when they expect ABT to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
ABT thesis for this butterfly
The market-implied 1-standard-deviation range for ABT extends from approximately $77.53 on the downside to $91.47 on the upside. A ABT long call butterfly is a pinning play: it pays maximum at the middle strike if ABT settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current ABT IV rank near 65.68% is mid-range against its 1-year distribution, so the IV signal is neutral; the butterfly thesis on ABT should anchor more to the directional view and the expected-move geometry. As a Healthcare name, ABT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ABT-specific events.
ABT butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ABT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ABT alongside the broader basket even when ABT-specific fundamentals are unchanged. Always rebuild the position from current ABT chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on ABT?
- A butterfly on ABT is the butterfly strategy applied to ABT (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With ABT stock trading near $84.50, the strikes shown on this page are snapped to the nearest listed ABT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ABT butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the ABT butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 28.79%), the computed maximum profit is $366.96 per contract and the computed maximum loss is -$125.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ABT butterfly?
- The breakeven for the ABT butterfly priced on this page is roughly $80.14 and $87.75 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ABT market-implied 1-standard-deviation expected move is approximately 8.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on ABT?
- Butterflies on ABT are pinning bets - traders use them when they expect ABT to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current ABT implied volatility affect this butterfly?
- ABT ATM IV is at 28.79% with IV rank near 65.68%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.